Asunto(s)
Aminofenoles , Benzodioxoles , Creatina Quinasa , Fibrosis Quística , Combinación de Medicamentos , Indoles , Pirazoles , Rabdomiólisis , Adolescente , Humanos , Aminofenoles/efectos adversos , Aminofenoles/uso terapéutico , Benzodioxoles/efectos adversos , Benzodioxoles/uso terapéutico , Creatina Quinasa/sangre , Fibrosis Quística/tratamiento farmacológico , Fibrosis Quística/complicaciones , Indoles/efectos adversos , Pirazoles/efectos adversos , Piridinas/efectos adversos , Piridinas/uso terapéutico , Pirroles/efectos adversos , Pirrolidinas , Quinolinas/efectos adversos , Quinolinas/uso terapéutico , Quinolonas/efectos adversos , Quinolonas/uso terapéutico , Rabdomiólisis/inducido químicamente , Tiofenos/efectos adversos , Tiofenos/uso terapéuticoRESUMEN
BACKGROUND: An increase in acute severe hepatitis of unknown aetiology in previously healthy children in the UK in March, 2022, triggered global case-finding. We aimed to describe UK epidemiological investigations of cases and their possible causes. METHODS: We actively surveilled unexplained paediatric acute hepatitis (transaminase >500 international units per litre) in children younger than 16 years presenting since Jan 1, 2022, through notifications from paediatricians, microbiologists, and paediatric liver units; we collected demographic, clinical, and exposure information. Then, we did a case-control study to investigate the association between adenoviraemia and other viruses and case-status using multivariable Firth penalised logistic regression. Cases aged 1-10 years and tested for adenovirus were included and compared with controls (ie, children admitted to hospital with an acute non-hepatitis illness who had residual blood samples collected between Jan 1 and May 28, 2022, and without known laboratory-confirmed diagnosis or previous adenovirus testing). Controls were frequency-matched on sex, age band, sample months, and nation or supra-region with randomised selection. We explored temporal associations between frequency of circulating viruses identified through routine laboratory pathogen surveillance and occurrence of cases by linear regression. SARS-CoV-2 seropositivity of cases was examined against residual serum from age-matched clinical comparison groups. FINDINGS: Between Jan 1 and July 4, 2022, 274 cases were identified (median age 3 years [IQR 2-5]). 131 (48%) participants were male, 142 (52%) were female, and one (<1%) participant had sex data unknown. Jaundice (195 [83%] of 235) and gastrointestinal symptoms (202 [91%] of 222) were common. 15 (5%) children required liver transplantation and none died. Adenovirus was detected in 172 (68%) of 252 participants tested, regardless of sample type; 137 (63%) of 218 samples were positive for adenovirus in the blood. For cases that were successfully genotyped, 58 (81%) of 72 had Ad41F, and 57 were identified as positive via blood samples (six of these were among participants who had undergone a transplant). In the case-control analysis, adenoviraemia was associated with hepatitis case-status (adjusted OR 37·4 [95% CI 15·5-90·3]). Increases in the detection of adenovirus from faecal samples, but not other infectious agents, in routine laboratory pathogen surveillance correlated with hepatitis cases 4 weeks later, which independently suggested an association (ß 0·06 [95% CI 0·02-0·11]). No association was identified for SARS-CoV-2 antibody seropositivity. INTERPRETATION: We observed an association between adenovirus 41F viraemia and paediatric acute hepatitis. These results can inform diagnostic testing recommendations, clinical management, and exploratory in vitro or clinical studies of paediatric acute hepatitis of unknown aetiology. The role of potential co-factors, including other viruses and host susceptibility, requires further investigation. FUNDING: None.
Asunto(s)
COVID-19 , Hepatitis , Preescolar , Femenino , Humanos , Masculino , Enfermedad Aguda , Estudios de Casos y Controles , SARS-CoV-2 , Reino Unido/epidemiologíaRESUMEN
We report a rapid increase in enterovirus D68 (EV-D68) infections, with 139 cases reported from eight European countries between 31 July and 14 October 2021. This upsurge is in line with the seasonality of EV-D68 and was presumably stimulated by the widespread reopening after COVID-19 lockdown. Most cases were identified in September, but more are to be expected in the coming months. Reinforcement of clinical awareness, diagnostic capacities and surveillance of EV-D68 is urgently needed in Europe.
Asunto(s)
COVID-19 , Enterovirus Humano D , Infecciones por Enterovirus , Enterovirus , Mielitis , Infecciones del Sistema Respiratorio , Control de Enfermedades Transmisibles , Brotes de Enfermedades , Enterovirus Humano D/genética , Infecciones por Enterovirus/diagnóstico , Infecciones por Enterovirus/epidemiología , Europa (Continente)/epidemiología , Humanos , Mielitis/epidemiología , SARS-CoV-2RESUMEN
Dermatomyositis (DM) is a multi-system disease that results in chronic inflammation principally of the skin and striated muscle. Small blood vessel injury in the GI tract has been described in dermatomyositis, manifesting as bleeding, ulceration, pneumatosis intestinalis, and ultimately perforation. Recent histopathological studies have shown deposits in the capillaries of the skin, gastrointestinal tract, and brain of patients with dermatomyositis similar to that found in patients with Degos disease, suggesting these disease processes are closely related or represent varying degrees of severity on the same pathologic spectrum. We report a case of juvenile dermatomyositis (JDM) resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination rituximab and cyclophosphamide therapy. We systematically reviewed the literature detailing the medical and surgical treatments for gastrointestinal perforation in dermatomyositis, Degos-like dermatomyositis, and Degos disease. In addition to our case, as of October 2019, we identified 36 cases describing gastrointestinal perforation in patients with underlying dermatomyositis, 5 cases of Degos-like dermatomyositis and 17 cases of idiopathic Degos disease. Corticosteroid therapy was used widely for dermatomyositis and Degos-like dermatomyositis, while antiplatelet and anticoagulant medications were chiefly used for patients with idiopathic Degos disease. However, there were no cases that detailed the successful treatment of dermatomyositis or Degos disease with gastrointestinal perforation with rituximab alone or combined with cyclophosphamide. We report that rituximab, in combination with cyclophosphamide, can be used as a novel adjunctive therapy to successfully treat dermatomyositis with Degos-like gastrointestinal perforation.
Asunto(s)
Antirreumáticos/uso terapéutico , Dermatomiositis/diagnóstico , Perforación Intestinal/diagnóstico , Papulosis Atrófica Maligna/diagnóstico , Niño , Ciclofosfamida/uso terapéutico , Dermatomiositis/complicaciones , Dermatomiositis/tratamiento farmacológico , Diagnóstico Diferencial , Procedimientos Quirúrgicos del Sistema Digestivo , Enfermedades Duodenales/diagnóstico , Enfermedades Duodenales/terapia , Perforación del Esófago/diagnóstico , Perforación del Esófago/terapia , Femenino , Humanos , Perforación Intestinal/etiología , Perforación Intestinal/terapia , Enfermedades del Yeyuno/diagnóstico , Enfermedades del Yeyuno/terapia , Rituximab/uso terapéuticoRESUMEN
Behçet disease is a complex, multisystem disease characterized by recurrent oral and genital ulcerations. It rarely occurs in infants or children. Neonatal Behçet disease has been reported in infants whose ulcers resolve at or before 9 weeks of age. Few cases of neonatal Behçet disease persisting into childhood have previously been reported. We report the case of a 1-month-old infant who presented with severe recurrent genital ulcerations and at 6 months developed recurrent oral ulcerations. Her orogenital ulcerations continue to recur. Human leukocyte antigen testing revealed HLA-B51 and B44 positivity. This is a case of pediatric Behçet disease in the neonatal period. Behçet disease should be considered in the differential diagnosis of recurrent genital and oral ulcerations in infants and children.